ReviewCells2026
Heterogeneity of Cardiomyocyte Lipid Droplets and Their Pathophysiological Implications in Cardiovascular Diseases.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adult heart relies on fatty acid β-oxidation for energy, and cardiomyocyte lipid droplets (CLDs) are central to myocardial lipid homeostasis. CLDs are now recognized to protect cardiomyocytes against lipotoxicity, endoplasmic reticulum (ER) stress, oxidative stress, and nutrient deprivation. Moreover, accumulating evidence suggests that CLDs within the same cardiomyocyte are not uniform but may exhibit heterogeneity in size, subcellular localization, protein composition, and metabolism. Here, we propose a conceptual framework that classifies CLD heterogeneity along three dimensions: morphology, organelle connectivity, and molecular composition. We first define the biological characteristics of CLDs and categorize their heterogeneity. We then discuss the molecular pathways maintaining this heterogeneity, their roles in the healthy heart, and their dysregulation in cardiovascular diseases. Finally, we review preclinical strategies targeting CLD heterogeneity and outline challenges and future directions for clinical translation. This framework integrates current evidence while acknowledging that direct molecular validation awaits future single-droplet omics technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.